Recs

3

Top-Rated Stocks That Treat Shareholders Right

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

The flip side to shareholder-friendly stocks expected to underperform the market? Highfliers that pay little heed to their owners' interests. There are also top-flight companies that treat their shareholders with respect.

Institutional Shareholder Services -- the big name in corporate proxies -- measures how well a company performs in as many as 63 categories, covering four broad areas. Moreover, each company is scored relative to its market index and its industry group. It assigns the stocks a rating that it calls it Corporate Governance Quotient, or CGQ.

Some evidence supports the notion that companies with weaker governance have higher risk, decreased profitability, and lower valuations. In this column, we'll be looking at stocks that Motley Fool CAPS investors have marked to outperform the market and that also sport above-average CGQ scores, either in their index group or among industry peers.

Company

CAPS Rating

(5 max)

Index CGQ Ranking*

Industry CGQ Ranking*

ExxonMobil (NYSE: XOM  )

****

77.9%

98.1%

Pfizer (NYSE: PFE  )

****

75.4%

99.3%

SanDisk (Nasdaq: SNDK  )

****

73.8%

97.5%

Automatic Data Processing (NYSE: ADP  )

*****

82.7%

98.9%

Western Refining (NYSE: WNR  )

****

50.7%

52.4%

Source: Yahoo! Finance, Motley Fool CAPS.
*Relative placement when compared to companies in index or industry. Higher is better.

Although finding good companies and holding them for the long term is one of the greatest secrets to investing, there are many factors that an investor should consider when deciding whether a company is good, and how well it treats shareholders shouldn't be least among them. View these rankings as a way to gauge how these businesses stack up against one another relative to their shareholder policies.

Go to the head of the class
After 27 years, oil companies are once again permitted to seek federal leases to drill for oil off the Atlantic and Pacific coastlines. Whether the change will have a practical impact is another question, since the Minerals Management Service doesn't have plans to consider new federal leases anytime soon. Yet the symbolic nature of the ban's expiration may eventually allow companies like ExxonMobil or Chevron (NYSE: CVX  ) to drill off the more important coast of Florida, which is covered by a separate ban.

Still, CAPS member altonoch likes the potential that ExxonMobil brings to the table:

Lifting of drilling bans offshore US, contracts in Iraq, large amounts of cash, necessity for energy for creation of global infrastructure, excellent management

If pharmaceutical companies can't develop sufficient drugs internally, they can always buy a biotech to boost their all-important drug pipelines. Bristol-Myers Squibb (NYSE: BMY  ) , for example, is trying to buy ImClone Systems and its Erbitux cancer drug. Earlier this year, Pfizer bought Encysive Pharmaceuticals to bolster its R&D efforts. CAPS All-Star member TDRH finds Pfizer a compelling value despite its empty pipeline:

Yes the pipleine is dry, yes it was a value trap when I bought it at $23.50, but the 6.9% dividend yield should keep this one from falling further and could preserve capital. Still positive cash flow and AAA rating, does not need to borrow money for operations, still feeding of the cash cows near expiry.

A Foolish quotient
Many factors go into whether a stock is a buy or sell, but do corporate governance policies enter into your equation? It pays to start your own research on these stocks on Motley Fool CAPS. Read a company's financial reports, scrutinize key data and charts, and examine the comments your fellow investors have made -- all from a stock's CAPS page.

Best Odds in the Universe!
If you're interested in a 98.79% chance at beating the market... and a 70.84% chance at DOUBLING the market's return – Motley Fool Supernova could be just what you're looking for. And get this: We arrived at these odds from 10,000 random back-tested portfolios composed of Motley Fool Co-founder David Gardner's personal stock picks.

It's why David recently handpicked a small team of world-class portfolio managers. You see, he thinks these odds can get even better! And he'd like to prove it to you...

Simply enter your email address. And the answer to the question everybody is asking will be delivered to your inbox!

Pfizer is a Motley Fool Income Investor and a Motley Fool Inside Value recommendation. Try any of our Foolish newsletters today, free for 30 days.

Fool contributor Rich Duprey does not have a financial position in any of the stocks mentioned in this article. You can see his holdings here. The Motley Fool has a disclosure policy.


Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

DocumentId: 745857, ~/Articles/ArticleHandler.aspx, 2/15/2012 3:31:34 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 5 hours ago Sponsored by:
DOW 12,878.28 4.24 0.03%
S&P 500 1,350.50 -1.27 -0.09%
NASD 2,931.83 0.44 0.02%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

2/14/2012 4:00 PM
SNDK $47.00 Up +0.37 +0.78%
SanDisk Corp CAPS Rating: ****
WNR $18.11 Up +0.22 +1.23%
Western Refining,… CAPS Rating: *****
XOM $84.67 Up +0.25 +0.30%
ExxonMobil Corp CAPS Rating: ****
PFE $21.33 Up +0.03 +0.14%
Pfizer, Inc. CAPS Rating: ****
ADP $54.25 Up +0.02 +0.04%
Automatic Data Pro… CAPS Rating: ****
BMY $31.85 Down -0.14 -0.44%
Bristol-Myers Squi… CAPS Rating: ****
CVX $106.49 Up +0.11 +0.10%
Chevron Corp CAPS Rating: *****

Advertisement